Matching articles for "page 100"
Issue 1327 · December 14, 2009
Drugs Past Their Expiration Date

Healthcare providers are often asked if patients can use drugs after their expiration date. Pharmaceutical companies, because of legal restrictions and liability concerns, will not sanction such use and might…

Med Lett Drugs Ther. 2009 Dec 14; 51(1327):100-1
Healthcare providers are often asked if patients can use drugs after their expiration date. Pharmaceutical companies, because of legal restrictions and liability concerns, will not sanction such use and might not even comment on the safety or effectiveness of using their products beyond the date on the label. Since the last Medical Letter publication on this subject, more data have become available.
Issue 1301 · December 15, 2008 Free
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness,…

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):100-3
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression. Click here to view the free full article.
Issue 1275 · December 3, 2007 Free
In Brief: Dexrazoxane for Anthracycline Extravasation

The FDA has approved a new formulation of dexrazoxane (Totect) for treatment of extravasation from intravenous (IV) anthracyclines such as doxorubicin ( Adriamycin , and others). Dexrazoxane has been available…

Med Lett Drugs Ther. 2007 Dec 3; 49(1275):100
The FDA has approved a new formulation of dexrazoxane (Totect) for treatment of extravasation from intravenous (IV) anthracyclines such as doxorubicin ( Adriamycin , and others). Dexrazoxane has been available since 1995 as Zinecard for protection against the cardiac toxicity of anthracyclines (Med Lett Drugs Ther 1995; 37:110) . It is also available generically. The drug’s precise mechanism of action is not known, but anthracyclines are vesicants that bind to DNA and act as oxidizing agents in the presence of iron. Dexrazoxane is a topoisomerase inhibitor, possibly interfering with anthracycline effects on DNA, and is also a potent iron-chelating agent, preventing free-radical formation. In uncontrolled clinical trials, dexrazoxane appears to have prevented severe necrosis that would require surgical debridement (HT Mouridsen et al. Ann Oncol 2007; 18:546. epub) . It is given in a dose of 1000 mg/m 2 (2000 mg maximum) as an IV infusion over 1-2 hours as soon as possible (no later than 6 hours) after extravasation has occurred and again 24 hours later, and then in a dose of 500 mg/m 2 (1000 mg maximum) 48 hours after the first dose. The dose should be reduced by half in patients with a creatinine clearance <40 mL/min. Download U.S. English
Issue 1275 · December 3, 2007
Addendum: Probiotics

( Vol. 49, p. 66, August 13, 2007 ) A reader has pointed out that Saccharomyces boulardii is not a separate species, but a strain of Saccharomyces cerevisiae . S. cerevisiae (including S. boulardii ) has been…

Med Lett Drugs Ther. 2007 Dec 3; 49(1275):100
( Vol. 49, p. 66, August 13, 2007 ) A reader has pointed out that Saccharomyces boulardii is not a separate species, but a strain of Saccharomyces cerevisiae . S. cerevisiae (including S. boulardii ) has been reported to cause systemic infection after oral ingestion in both immunocompromised patients and healthy hosts (MJ McCullough et al. J Clin Microbiol 1998; 36:2613).